NCT07303712 Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
| NCT ID | NCT07303712 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Palo Alto Veterans Institute for Research |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 12 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12 participants in total. It began in 2024-08-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Eligibility Criteria
Inclusion Criteria: 1. Age \> or = 18 years 2. HCC confirmed on imaging, BCLC stage 0, A, B, or C 3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board - Exclusion Criteria: 1. Not eligible for Y90 procedure 2. Prior surgery or ablation on indicated tumors 3. Patient unable to complete the follow up visits required for clinical care or research -
Contact & Investigator
Sirish Kishore, MD
PRINCIPAL INVESTIGATOR
VA Palo Alto Health Care System
Frequently Asked Questions
Who can join the NCT07303712 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07303712 currently recruiting?
Yes, NCT07303712 is actively recruiting participants. Contact the research team at sirish.kishore@va.gov for enrollment information.
Where is the NCT07303712 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT07303712 clinical trial?
NCT07303712 is sponsored by Palo Alto Veterans Institute for Research. The principal investigator is Sirish Kishore, MD at VA Palo Alto Health Care System. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.